Cyrus Pipeline
Program | Mode/Partner | Discovery | Optimization | Preclinical |
Infused enzyme: chronic disease* | In-house | ✔ | ||
COVID19/ACE2 receptor decoy# | In-house | ✔ | ✔ | ✔ |
hCMV receptor decoy# | In-house | ✔ | ✔ | |
Infused enzyme: Rare disease 1* | Taktos Therapeutics | ✔ | ✔ | |
Infused enzyme: Rare disease 2* | Taktos Therapeutics | ✔ | ||
Gene therapy deimmunization* | Taktos Therapeutics | ✔ | ✔ | |
Autoimmunity/IL2# | Selecta Biosciences | ✔ | ||
CRISPR# | Broad Institute | ✔ | ||
Metabolic disease target# | Partnered | ✔ |
*These programs, which include various aspects of protein design have a common core, which is deimunization of the infused protein
#These programs include multiple design elements and are not focused on deimmunzation
INTERESTED IN
PARTNERING WITH US ON
PROTEIN THERAPEUTICS?